Tag: Phase 3 study

January 29, 2020

Intercept Completes Phase 3 Enrollment of Cirrhosis Treatment

Intercept has completed patient enrollment in its Phase 3 study evaluating obeticholic acid for the treatment of cirrhosis due to...
January 14, 2020

Alexion Confirms Planned Phase 3 Study of ALS Treatment

Alexion announced that is plans to start a Phase 3 study of ULTOMIRIS (ravulizumab) in amyotrophic lateral sclerosis (ALS).
October 11, 2019

RedHill Biopharma Releases Positive Results from MAP US Phase 3 Study

The company announced positive results from its MAP US Phase 3 Study and MAP US2 Open-Label Extension Study
August 22, 2019

Retrophin Announces Topline Results from Phase 3 FORT Study

Retrophin (NASDAQ:RTRX) has announced that the Phase 3 FORT study evaluating the safety and efficacy of fosmetpantotenate compared to a...
May 9, 2018

Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update

Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 26, 2018

Kalytera Issues CEO Letter to Shareholders

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today issued the following letter to shareholders from the Company’s President...